Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-03-03 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司、高盛高华证券有限责任公司关于百济神州有限公司关于公司高级管理人员暨核心技术人员拟离职的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed report from two financial institutions acting as joint sponsors regarding the proposed resignation of a senior management and core technical personnel member, Dr. Jane Huang, from BeiGene Ltd. It includes extensive information about the individual's role, impact of departure, succession plans, confidentiality agreements, shareholding, and the sponsor's verification and opinion on the matter. The content focuses on management changes and their implications rather than financial results, regulatory compliance, or shareholder voting. There is no indication that this is an announcement of a report publication or a brief notice. The document is not a financial report, earnings release, or legal proceeding update. It is a formal management-related disclosure about a senior executive's departure and related corporate governance matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (7448 characters) supports it being a full report rather than a brief announcement.
2022-03-03 Chinese
百济神州有限公司关于公司高级管理人员暨核心技术人员拟离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management and core technical personnel, Dr. Jane Huang, from the position of Chief Medical Officer of Hematology at BeiGene Ltd. It details the departure, the transition plan, the impact on the company, and the measures taken to ensure continuity. The document includes information about the individual's role, responsibilities, and the company's response to the change. There are no financial statements, earnings data, or regulatory filings related to financial performance. The focus is on management changes at a senior level. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about the management change, not just a brief notice or regulatory filing.
2022-03-03 Chinese
港股公告：授出购股权
Director's Dealing Classification · 95% confidence The document is a detailed announcement about the granting of share options (stock options) under the company's 2016 Option and Incentive Plan. It includes specifics such as the number of options granted, exercise price, vesting schedule, and recipients, including independent non-executive directors. The document references compliance with listing rules and provides detailed terms of the share option grants. It is not a full financial report, earnings release, or management discussion. It is not a proxy statement or AGM material. It is a regulatory announcement about share-based compensation, specifically the granting of stock options to directors and employees. This fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives, including share option grants. The document length is about 2780 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the classification is DIRS with high confidence.
2022-03-03 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands, and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document includes detailed tables of share issuance and repurchase data, dates, share prices, and percentages, as well as confirmations that the share issuances were authorized and complied with regulatory requirements. The document is not an announcement of a report but the actual disclosure itself, containing substantive data on share capital changes. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2022-03-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document details share issuance under a share award plan, including dates, share counts, and prices. It also includes formal confirmations by company officers regarding the authorization and compliance of the share issuance. The document length is 2888 characters, which is relatively short but contains detailed data on share issuance and capital changes, not merely an announcement of a report or a certification. This fits the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or other capital changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2022-02-28 Chinese
港股公告：董事名单及其角色与职能
Governance Information Classification · 100% confidence The document lists the members of the board of directors and their roles in various board committees, including audit, remuneration, nomination and corporate governance, scientific advisory, and business and medical affairs advisory committees. It provides detailed governance structure information about the company's board and committees. There is no financial data, no mention of a report being attached or published, and no indication of other types of filings such as earnings, capital updates, or legal proceedings. This content fits the definition of Governance Information (CGR), which details the company's internal rules, board structure, and governance practices.
2022-02-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.